Stockreport

Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Post...

Atara Biotherapeutics, Inc.  (ATRA) 
Last atara biotherapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.atarabio.com/investor-relations
PDF Sustained Disability Improvements Seen at Six Months Were Maintained at 12 Months with ATA188Potential Therapeutic Response with ATA188 Supports Role of Epstein-Barr Vir [Read more]